Online inquiry

IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4799MR)

This product GTTS-WQ4799MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DPP4 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001379604.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1803
UniProt ID P27487
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4799MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3448MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ13057MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ3614MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ10069MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ12702MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ8265MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ5472MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ7210MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW